Clinical case of benralizumab use in severe eosinophilic bronchial asthma in the Republic of Dagestan

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article presents the results of the examination, observation, and treatment of a patient with severe persistent bronchial asthma with an eosinophilic phenotype who received benralizumab (Fazenra) in a complex treatment. Benralizumab is indicated for patients with severe bronchial asthma with an eosinophilic phenotype in adult patients as an additional maintenance therapy, in which the use of glucocorticosteroids does not achieve control over the symptoms of the disease. With complex therapy, the inclusion of benralizumab led to positive dynamics of both clinical symptoms and indicators of respiratory function, which allowed us to reduce the volume of therapy with corticosteroids and achieve disease control. The above case is of interest to both pulmonologists and therapists.

Full Text

Restricted Access

About the authors

Seypula Sh. Akhmedkhanov

Dagestan State Medical University

Author for correspondence.
Email: saip@mail.ru
ORCID iD: 0000-0002-8935-220X
SPIN-code: 2620-0049

MD, Dr. Sci. (Med.), Professor

Russian Federation, 1 Lenin Square, Makhachkala, 1367000

Saida G. Gadzhiyeva

Dagestan State Medical University

Email: saidagadzh@yandex.ru
ORCID iD: 0009-0005-0488-7619

Department Assistant

Russian Federation, 1 Lenin Square, Makhachkala, 1367000

Albina T. Beybalayeva

Dagestan State Medical University

Email: beybalaeva89@mail.ru
ORCID iD: 0000-0002-3443-7118
Russian Federation, 1 Lenin Square, Makhachkala, 1367000

Zaira M. Saidova

Dagestan State Medical University

Email: saidova7997.z@gmail.com
ORCID iD: 0000-0003-2709-3553
SPIN-code: 5531-3174
Russian Federation, 1 Lenin Square, Makhachkala, 1367000

References

  1. Asthma. Key facts [Internet] WHO. Available from: http://www.who.int/ru/news-room/fact-sheets/detail/asthma. Accessed 26.09.2021.
  2. Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention (2022 updated) [Internet]. Available from: https://ginasthma.org. Accessed: 17.11.2023.
  3. Bystritskaya EV, Bilichenko TN. Review of the general incidence of bronchial asthma in the population of the Russian Federation. Pulmonologia. 2022;32(5):651–660. (In Russ.) doi: 10.18093/0869-0189-2022-32-5-651-660
  4. Belevsky AS, Zaitsev AA. Pharmacoeconomical aspects of bronchial asthma therapy: real clinical practice. Medical Council. 2018;(15):60–68. (In Russ.) doi: 10.21518/2079-701X-2018-15-60-68
  5. Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108:1723–1732. doi: 10.1016/j.rmed.2014.10.007
  6. Sergeeva G, Emelyanov A, Leshenkova E, Znakhurenko A. Biomarkers of eosinophilic airways inflammation in patients with severe asthma: a reallife study. Allergy. 2019;74(S106):ТР0640. doi: 10.1111/all.13961
  7. Tran TN, Khatry DB, Ke X, et al. High blood eosinophil count is associated with more frequent asthma. Ann Allergy Asthma Immunol. 2014;113(1):19–24. doi: 10.1016/j.anai.2014.04.011
  8. Avdeev SN, Nenasheva NM, Zhudenkov KV, et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in the Russian Federation. Pulmonology. 2018;28(3):341–358. (In Russ.) doi: 10.18093/0869-0189-2018-28-3-341-358
  9. Federal’nye klinicheskie rekomendatsii: Bronkhial’naya astma. 2021. [Internet] 16.06.2023. Available from: https://cr.minzdrav.gov.ru/recomend/359_2. Accessed: 17.11.2023. (In Russ.)
  10. Global Initiative for Asthma. Difficult-to-treat severe asthma in adolescent and adult patients. Diagnosis and Management. 2022 [Internet]. Available from: https://ginasthma.org. Accessed: 17.11.2023.
  11. Arkhipov VV, Grigorieva EV, Gavrishina EV. Control of bronchial asthma in Russia: results of a multicenter observational study of NIKA. Pulmonology. 2011;(6):87–93. (In Russ.) doi: 10.18093/0869-0189-2011-0-6-87-93
  12. Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors: systematic review. Eur Respir J. 2018;52(5):1801–1393. doi: 10.1183/13993003.01393-2018
  13. Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58. doi: 10.1016/S2213-2600(21)00352-0
  14. FitzGerald JM, Bleecker ER, Nair P et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi: 10.1016/S0140-6736(16)31322-8
  15. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. doi: 10.1016/S0140-6736(16)31324-1
  16. Bao-ping T, Gen-sheng Z, Jian L, et al. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. Journal of Asthma. 2017. doi: 10.1080/02770903.2017.1379534
  17. Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9(12):4381–4392.e4. doi: 10.1016/j.jaip.2021.07.058

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70763 от 21.08.2017 г.